Peter Wostyn

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Peter Wostyn, MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, Belgium[1] and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.[2]

Dr Wostyn developed the unproven glymphatic dysfunction hypothesis which postulates that a dysfunction of the waste clearance system, called the glymphatic system, causes a build-up of toxins within the central nervous system, which he hypothesised precipitates at least some cases of ME/CFS.[3]


Notable studies[edit | edit source]

  • 2018, Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?[4]
  • 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy[3] - (Abstract)
  • 2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction[5]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Peter Wostyn". LinkedIn. October 22, 2019.
  2. "Technology - P&X Medical". px-medical.be. Retrieved October 22, 2019.
  3. 3.0 3.1 Wostyn, Peter; De Deyn, Peter Paul (September 2018). "The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy". Medical Hypotheses. 118: 142–145. doi:10.1016/j.mehy.2018.07.007.
  4. Wostyn, Peter; De Deyn, Peter Paul (September 2018). "Can cerebrospinal fluid diversion be beneficial in the treatment of chronic fatigue syndrome?". Medical Hypotheses. 118: 174. doi:10.1016/j.mehy.2018.04.020.
  5. Wostyn, Peter (October 4, 2019). "Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction". Medical Hypotheses. 134: 109416. doi:10.1016/j.mehy.2019.109416. ISSN 1532-2777. PMID 31622921.